TORONTO, Dec.
13, 2018 (GLOBE NEWSWIRE) -- Khiron Life Sciences Corp., an integrated medical cannabis company
with its core operations in Colombia, is pleased to announce that, further to
press releases issued on Aug. 7, 2018 and Oct. 24, 2018, the Company has
completed its acquisition of the Latin American Institute of Neurology and the
Nervous System (ILANS).
ILANS is a growing health service
network provider in Colombia and Latin America.
The ILANS
network represents 100,000 patients in Colombia and will position Khiron with
approximately C$10.5 Million in gross revenue and C$1.8 Million of EBITDA (2017
Audited Financial Statements). The ILANS acquisition provides a secure and
scalable revenue stream and opportunity to enhance profitability from
introducing medical cannabis to ILANS patients.
